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Abstract
Background—Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or 
responsive, representing two entities known as eosinophilic esophagitis (EoE) and PPI-responsive 
esophageal eosinophilia (PPI-REE), respectively. Although they present with similar clinical 
features, EoE is accepted to be an antigen–driven, Th2-associated allergic disorder, whereas the 
etiology of PPI-REE remains a mystery.
Objective—In this study, our aim was to investigate the pathogenesis of PPI-REE using a 
recently described esophageal based EoE diagnostic panel (EDP) composed of a set of 94 
esophageal transcripts, and to determine if PPI therapy reverses any esophageal transcriptional 
abnormalities.
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Methods—We evaluated the EDP signature in biopsy samples obtained from adult and pediatric 
PPI-REE subjects from four institutions and compared the pre and post PPI therapy expression 
profiles of these subjects with those of active EoE subjects.
Results—The EDP identified EoE from control subjects with 100% accuracy amongst the four 
clinical sites. Bioinformatic analysis revealed largely overlapping transcriptomes between PPI-
REE and EoE, including the genes for eosinophil chemotaxis (CCL26), barrier molecules (DSG1), 
tissue remodeling (POSTN), and mast cells (CPA3). After PPI-mono therapy, PPI treatment alone 
almost completely reversed the allergic inflammatory transcriptome of PPI-REE. Furthermore, we 
identified a set of candidate genes to differentiate EoE from PPI-REE before treatment.
Conclusion—These findings provide definitive evidence that PPI-REE is a disease entity with 
significant molecular overlap with EoE, suggesting that many subjects with PPI-REE represent a 
continuum of the same pathogenic allergic mechanisms that underlie EoE and thus may constitute 
a sub-phenotype of EoE. The ability of PPI therapy to nearly entirely reverse gene expression 
associated with PPI-REE particularly that associated with classic features of allergic inflammation 
provides new insight into potential disease etiology and management strategies for patients with 
significant esophageal eosinophilia.
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INTRODUCTION
Esophageal eosinophilia occurs in a number of disorders including gastroesophageal reflux 
disease (GERD), Crohn’s disease, Celiac disease and eosinophilic esophagitis (EoE), a 
clinico-pathological chronic upper gastrointestinal (GI) disorder defined by esophageal 
dysfunction and eosinophil infiltration of ≥15 eosinophils per high-power field (HPF). 
Translational research in the past 10 years has uncovered a food allergen–driven, Th2 cell-
immune–mediated disease pathogenesis1, 2. Since gastroesophageal reflux disease (GERD) 
may also elicit esophageal eosinophilia, a consensus recommendation for the diagnosis of 
EoE3, 4 requires a proton-pump inhibitor (PPI) trial to exclude the possibility of acid-
induced esophageal eosinophilia. Although EoE is defined by a failed PPI trial, another form 
of esophageal eosinophilia that is frequently observed features tissue eosinophil levels as 
high as EoE (in contrast to GERD), diffuse infiltration along the esophageal length, and 
clinical characteristics representative of EoE, but PPI mono-therapy is effective in reversing 
both histologic and clinical abnormalities5. A number of explanations have been proposed 
including 1) the blockade of GERD-associated inflammation by the inhibition of acid by 
PPI; 2) the anti-inflammatory effect of PPI, such as inhibition of eotaxin-3 and STAT66 and 
3) the interaction of acid and food allergens. Due to the lack of a clear understanding of the 
natural history and pathogenesis, this enigmatic condition is currently termed “PPI-
responsive esophageal eosinophilia” (PPI-REE). The frequency of PPI-REE among all 
patients with esophageal eosinophilia (≥15 eosinophils/HPF) is substantial, with ranges from 
10–50%7–10.
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Defining the underlying mechanisms of this inflammation in patients with PPI-REE will 
help to guide appropriate therapeutic strategies. However, to date, there have been no 
molecular, cellular, endoscopic, clinical markers, or pH testing that clearly distinguishes 
these entities from one another. EoE is treated with topical corticosteroids and/or dietary 
eliminations, whereas PPI-REE is treated, at least transiently, with acid suppression10. 
Currently, it remains to be determined whether these two entities involve the same or 
different molecular pathogenesis. An understanding of their molecular similarities and 
differences would provide diagnostic and therapeutic clarity for practitioners and patients 
since both PPI-REE and EoE are clinically similar in terms of clinical symptoms, 
endoscopic findings, male predominance, and high rate of atopy8, 9.
Substantial progress has been made with regard to the molecular etiology of EoE by using 
whole-genome transcript expression profiling of esophageal tissue1. Recently, a molecular 
EoE diagnostic panel (EDP) was identified that is composed of 94 EoE genes and 
distinguishes EoE from control individuals without esophagitis or with GERD11. Although 
the EDP has been reported to have excellent accuracy (>96% sensitivity and specificity), it 
has only been applied to patients from one institution and has not been previously applied to 
PPI-REE. In light of these points, this retrospective study using archived tissues aimed to 
answer the following crucial questions: 1) does PPI-REE possess a typical EoE molecular 
signature, characteristic of allergic inflammation, as defined by the EDP or a unique gene 
expression profile?; 2) does remission induced by PPI-mono therapy lead to transcript 
signature reversal?; 3) does the gene dysregulation in PPI-REE correlate with eosinophilia at 
the molecular level, similar to that in EoE?11; and finally, 4) are there gene expression 
profiles that can differentiate PPI-REE and EoE before a therapeutic PPI trial, that is a 
priori? Herein we report that PPI-REE before PPI therapy has a molecular signature that is 
similar to EoE. Further, this pre-therapy PPI-REE gene expression profile is reversed in 
parallel with PPI–induced remission. Finally and of particular clinical relevance, we identify 
a preliminary cluster of genes that is predictive for PPI-REE before intervention.
METHODS
Subject selection and study design
Previously collected and archived paraffin-embedded PPI-REE, EoE, GERD, and healthy 
control samples were obtained from five U.S. institutions: University of California, San 
Diego (UCSD)/Rady Children’s Hospital, San Diego; University of North Carolina - Chapel 
Hill (UNC); Walter Reed National Military Medical Center (WRNMMC); Cincinnati 
Children’s Hospital Medical Center (CCHMC); and Children’s Hospital Colorado 
(Supplemental Table 1). The inclusion criteria for PPI-REE, as well as EoE, GERD, and 
healthy controls (NL), were standardized prior to the experiments and data analysis. Experts 
from each institution agreed upon the definition and inclusion criteria and were directly 
involved in screening of PPI-REE subjects in their sites, identifying those with samples 
available pre and post PPI therapy, as well as determining samples from EoE, GERD, and 
NLs. Specifically, control subjects were defined by normal endoscopy, normal pathology 
with 0 eosinophils/HPF, and no known history of EoE. GERD subjects were defined by 
clinical symptoms consistent with reflux (e.g. heartburn, regurgitation), <15 peak 
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eosinophils/HPF on biopsy, and no previous EoE history. A portion of the GERD subjects 
from CCHMC were confirmed to have reflux by concurrent pH/impedance testing (MII-
pH)11, 12. EoE subjects were defined as having symptomatic esophageal dysfunction and 
≥15 peak esophageal eosinophils/HPF even after an 8–12–week PPI trial, as per consensus 
guidelines3, 4. PPI-REE subjects were defined as having symptoms consistent with 
esophageal dysfunction and initial esophageal eosinophilia ≥15 eosinophils/HPF on index 
endoscopy that resolved (<15 eosinophils/HPF) after an 8-week course of PPI therapy (20–
40 mg bid for adult or 10–30 mg bid for pediatric of available agents). All PPI-REE subjects 
exhibited symptomatic (improvement of symptoms by self-report at the time of the repeat 
endoscopy) and endoscopic improvements after a mono-therapy with PPI. Both adult (≥18 
years) and pediatric (<18 years) subjects were included in the study. All secondary causes of 
GI tract eosinophilia, including concomitant eosinophilic gastroenteritis, were excluded 
prior to confirming the diagnosis of EoE. Atopy was defined by clinical diagnoses and 
documented history of food allergies by either clinical reactions or skin testing. This study 
was approved by the Institutional Review Board (IRB) of the participating institutions.
EoE transcriptome PCR amplification by EDP
The EoE transcriptome was determined as reported previously using the EDP11 from RNA 
extracted from 60–80 μm tissue sections from formalin-fixed, paraffin-embedded (FFPE) 
blocks. Briefly, 500–1000 ng RNA was reverse transcribed to cDNA and subjected to the 
EDP amplification by the ABI 7900HT qPCR system. The data were then imported into 
Genespring (GX 12.5) software for implementation of the dual algorithm, namely cluster 
analysis and EoE score calculation. To compensate for the long archiving time for some of 
the FFPE samples, a 50% call rate filter was applied to the 77 definitive diagnostic genes11 
in order to focus on informative genes, resulting in a cluster of 59 genes (F59) that formed 
the basis of all of the following analyses.
Statistical and bioinformatic analysis
The transcriptomes of the entire cohort of 114 samples (from 96 independent subjects) were 
compared by clustering (the signature analysis), EoE score11 calculation, analysis of 
variance (ANOVA), and principal component analysis (PCA). Most of our algorithm tools 
were previously reported11. Briefly, an EoE score (F59) was derived from entities that 
passed a >50% call rate filter, resulting in 59 of the 77 diagnostic genes of EDP. With the 
individual EoE scores (F59) from the five subject groups (NL, GERD, EoE, PPI-REE before 
PPI treatment [PPI-REE-pre], PPI-REE after PPI treatment [PPI-RRE-post]), one-way 
ANOVA with Bonferroni’s multiple comparison post-test were used to identify all 
significant pairs. PCA was also used to generate a 3D plot of the top three variance 
contributors between the PPI-REE-pre and EoE cohorts, using the NL and PPI-REE-post 
cohorts as reference. Paired t-test was used to compare the treatment effect of paired 
samples before and after PPI. A two-tailed p value < 0.05 was deemed as statistically 
significant. For correlation analysis between eosinophil counts and gene dysregulation (EoE 
score [F59]), Spearman correlation was used to derive an r value and p value.
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A total of 114 FFPE samples from 96 individual subjects were analyzed. Subject age, 
demographics, clinical symptoms, endoscopic findings, and esophageal eosinophil levels of 
all groups are detailed in Table 1, and subject numbers stratified by group and center are 
given in Table S1. The age range for all subjects was 10 months to 72 years, with 40 
pediatric subjects (mean age 8.7 ± 5.1 years) and 56 adults (mean age 37.4 ± 13.5). The EoE 
and pre-therapy PPI-REE group (PPI-REE-pre) both had a male predominance (73% and 
75%, respectively), and the majority of clinical features between the EoE and PPI-REE-pre 
groups were similar. Some clinical and endoscopic findings differed significantly, with food 
impactions, esophageal strictures, luminal narrowing, linear furrows, and decreased 
vascularity being more common and a normal endoscopic appearance being less common in 
the EoE group compared to the PPI-REE-pre group (p < 0.05 for all, Table 1). Compared to 
the NL and GERD cohorts, EoE and PPI-REE groups have higher rates of atopic disease 
(Table 1, p=0.01 for both allergic rhinitis and food allergy, p=0.50 for eczema and p=0.78 
for asthma). At baseline, prior to PPI treatment, the maximum eosinophil count was higher 
in the EoE group than in the PPI-REE-pre group (114 vs. 56 eosinophils/HPF, p = 0.002). 
After the PPI trial, the eosinophil count remained elevated in the EoE group (72 eosinophils/
HPF) but markedly decreased in the PPI-REE group (4 eosinophils/HPF).
Untreated PPI-REE has an EDP signature that overlaps with EoE and reveals Th2-
associated allergic inflammation as the fundamental molecular pathogenesis
In order to address whether PPI-REE has an EoE-like genetic signature, we evaluated the 
transcriptome of PPI-REE-pre samples within the scope of representative EoE genes 
embedded on the EDP. As illustrated by the heat-map, the gene upregulation and 
downregulation pattern comprising the EoE hallmark gene signature was present in PPI-
REE-pre samples (Figure 1), including the elevated CCL26 levels for eosinophil 
chemotaxis, CPA3 for mastocytosis, IL-13 responding MUC4, and POSTN for tissue 
remodeling. There was a remarkable conservation of the EoE esophageal transcriptome in 
PPI-REE-pre. In contrast, this pattern was not present in the control, GERD, and treated 
PPI-REE (PPI-REE-post) groups.
For statistical comparison, individual signature quantification was performed by EoE 
scoring, which has been shown to directly reflect EoE disease activity11 (Figure 2A). Of 
note, when comparing the NL and EoE cohorts, a sensitivity of 100% and specificity of 
100% was achieved from these independent, non-CCHMC FFPE samples, demonstrating a 
high merit of the EDP with external FFPE samples. A receiver operating characteristic 
(ROC) analysis resulted in an area under the ROC curve (AUC) of 1.0 (Figure 2B). 
Compared by ANOVA with Bonferroni multiple comparison post-test (Figure 2A, lower 
panel), the NL and GERD cohorts were significantly different from the EoE cohort. Despite 
their comparable signature pattern (Figure 1), there was a small but significant difference in 
EoE score between PPI-REE-pre and EoE, with EoE being molecularly more severe (more 
pronounced signature [Figure 1] and lower EoE score [Figure 2A]), and there was a small 
group of heterogeneous subjects (Figure 2A). This observed magnitude difference between 
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EoE and PPI-REE-pre also held true after the EoE score was normalized to eosinophils/HPF 
(Figure 2C and 2D), suggesting that although untreated PPI-REE appears to be within the 
same molecular spectrum as EoE, untreated PPI-REE is not as altered as classical EoE in 
terms of its transcriptome. When the expression profiles of NL, EoE, PPI-REE-pre, and PPI-
REE-post were plotted in three dimensions by principal component analysis (PCA, used as a 
dimensionality reduction method), with each axis representing one of the top three variance 
contributors, PPI-REE-pre was geometrically close to EoE (Figure 2E). In contrast, NL and 
PPI-REE-post clustered together (Figure 2E). Correlation of EoE score and eosinophils/HPF 
for all FFPE samples indicated a robust molecular-histological linkage (Figure 2F, r = −0.81, 
p < 0.0001). There was a mild but significant correlation between the EoE score and 
eosinophils/HPF in EoE samples but not in PPI-REE samples (Figure 2F). Notably, EoE and 
PPI-REE have a retained signature regardless of the age group, as indicated by comparable 
EoE score between pediatric and adult subjects (Supplemental Figure 1). Treatment with PPI 
did not modify the molecular signature of EoE in both NL and EoE cohort, as shown in 
Supplemental Figure 2 and a previous publication from our group1.
Besides the heat-map (signature) and EoE score (disease severity) comparisons, we 
performed additional analyses to address whether the transcriptome of EoE’s and PPI-REE’s 
are similar at the single gene level. First, when compared to NL reference, EoE and PPI-
REE-pre yielded a similar number of significant genes with comparable bi-directional 
distribution patterns, as illustrated by the volcano plots of fold change and p value (Figure 
3A). A large percentage of the significant genes (46 genes, vs. NL) overlapped between EoE 
and PPI-REE-pre (Figure 3B and Supplemental Table 2). There was a high correlation of the 
expression levels of these 46 common genes between EoE and PPI-REE (Figure 3C, R2 = 
0.85, p < 0.0001). Moreover, an ontology analysis on biological functions on these 46 
common genes revealed an overall image of Th2 allergic inflammation with high 
significance (Figure 3D), indicating a shared allergic inflammatory response between EoE 
and PPI-REE.
Molecular signature and mastocytosis of untreated PPI-REE are reversible by PPI-mono 
therapy
The histological eosinophilia associated with PPI-REE is responsive to PPI therapy, but it is 
not known whether the PPI-REE gene expression pattern normalizes after PPI. Among the 
15 paired PPI-REE-pre and PPI-REE-post samples, 13 of the PPI-REE-pre samples had 
molecular similarity to EoE as measured by EoE score (EoE score [F59] < 203, Figure 2A). 
On the basis of these 13 pairs, the significant EoE score (F59) reversal (Figure 4A, p < 
0.001, paired t-test PPI-REE-pre vs. PPI-REE-post) after PPI is consistent with the notion 
that PPI is sufficient to induce histological and symptomatic remission in PPI-REE. 
Mastocytosis is a hallmark for allergic inflammation; accordingly, we found that histological 
remission of PPI-REE following PPI therapy was accompanied by normalization of 
mastocytosis from paired samples (Figure 4B and 4C, tryptase IHC staining, p < 0.01, paired 
t-test, n = 10), consistent with the normalization of mast cell genes (CPA3 and TPSB2) by 
PPI therapy (Figure 4D and 4E). Although the overall signature normalized after PPI 
therapy, when individual expression of the EDP genes was compared between all PPI-REE-
post samples and NL samples, 8 EoE genes, including CCL26, POSTN, and DSG1, had 
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significantly different expression (p < 0.05, fold-change > 2.0, Figure 4F). These data 
indicate a pronounced and specific effect of PPI on the PPI-REE subject’s gene expression 
pattern, corroborating the histological remission.
Distinguishing untreated PPI-REE and EoE
Considering that EoE and PPI-REE-pre are clinically and histologically indistinguishable 
but different in their therapeutic response to PPI treatment, a molecular approach to identify 
PPI-REE before pharmaceutical intervention would be a transformative advance for patient 
care. To further molecularly differentiate these diseases, we collectively compared the EDP 
molecular signature of EoE and PPI-REE-pre cohorts at the individual gene level. A cluster 
of 10 genes was identified whose expression was significantly different in PPI-REE-pre as 
compared with EoE (Figure 5A, p < 0.05, fold change > 2.0). On the basis of these 10 
differentially expressed genes, a proposed protein-protein interaction network highlighted 
the potential involvement of chemotaxis systems, ion channel activities, and the ubiquitin/
proteasome system in differentiating the molecular pathogenesis between EoE and PPI-
REE-pre (Figure 5B). With a more stringent false-detection filter (Westfall-Young) applied, 
KCNJ2 (Potassium inwardly-rectifying channel, subfamily J, member 2/Kir2.1), became the 
only gene with significant differential expression (Figure 5C, p < 0.01, false-corrected p = 
0.04). It is notable that KCNJ2 was among the 4 genes that are specifically differentially 
expressed in EoE compared to NL, not in PPI-REE vs. NL (Figure 3B) and is indeed 
expressed in the esophagus13. For diagnostic merit, using KCNJ2 resulted in 72% sensitivity 
and 72% specificity to predict PPI-REE-pre versus EoE. KCNJ2 encodes the potassium 
channel Kir2.1, which is abundant in GI mucosa and co-localizes with the H+-K+-ATPase/
proton pump14, 15; therefore we propose a potential interaction between this potassium 
channel and proton pump in upper GI epithelium (Figure 5D).
DISCUSSION
An emerging body of data suggests that PPI therapy is effective at reducing and/or 
eliminating esophageal eosinophilic inflammation and has led to the emergence of a new 
disease entity, PPI-REE, yet this disease is not well understood. The relationship between 
PPI-REE and EoE remains enigmatic. Clinically, PPI-REE resembles EoE more than GERD 
as evidenced by the findings that 1) the tissue eosinophilia level of PPI-REE is usually 
higher than the level typically seen in GERD; 2) a high percentage of PPI-REE patients have 
atopy and/or food allergy, similar to EoE; and 3) both EoE and PPI-REE show a male 
predominance and Caucasian susceptibility9. It can be difficult to distinguish PPI-REE and 
EoE by clinical, endoscopic and histological features8, 9, thus leading to the question of 
whether similar mechanisms may govern their clinicopathological features. In this 
retrospective study, we show that untreated PPI-REE has a molecular signature that is 
overlapping with EoE, providing compelling evidence that the two diseases are part of the 
same spectrum of a Th2 associated disease process, in nearly all patients. It is notable that 
we identified a subset (~14%) of PPI-REE subjects that did not have an EoE-like signature 
prior to PPI therapy. Whether this finding represents heterogeneity in the biopsies samples 
or distinct pathogenesis will require future studies. One of the strengths of this study is the 
inclusion of both adult and pediatric subjects from multiple centers; we did not observe a 
Wen et al. Page 7






















major heterogeneity between adult and pediatric subjects in each cohorts, consistent with our 
previous reported similar EoE signature between adult and pediatric EoE subject11.
Moreover, the molecular signature of PPI-REE is almost completely reversible by PPI 
treatment, which does not modify the signature in EoE and NL cohorts. This is similar to 
what happens to the EoE signature after diet and/or glucocorticoid therapy11, 16. It is notable 
that we found that expression of eight of the EoE genes failed to normalize to that found in 
the NL individuals; perhaps these refractory genes may explain the clinically observed 
relapsing propensity of PPI-REE17. Given the ability of PPI to modulate multiple 
components of the inflammatory axis, such as chemokines6, 18, 19, interleukins20, and 
vascular cell adhesion molecules21 and mucosal barrier function22, the effects of high-dose, 
twice daily PPI may have an anti-inflammatory effect in addition to its effect on acid 
reduction19. Our study supports this hypothesis.
The observed EoE score was significantly more severe in EoE than PPI-REE-pre. Although 
the difference in eosinophils/HPF (EoE vs. PPI-REE-pre) may explain part of the variation, 
this difference was still significant after normalizing to eosinophils/HPF; however, this 
difference does not influence the general interpretation that EoE and PPI-REE have 
overlapping molecular signatures in addition to their similar clinicopathological features. 
Importantly, the CCL26 level in PPI-REE was robustly reduced by PPI therapy, consistent 
with the histological remission and the finding that PPI has an anti-inflammatory role by 
regulating CCL26 transcription activity6 and protein expression18. Concurrent with the 
decline in CCL26 levels, there was normalization of the mast cell genes (CPA3, TPSAB2), 
Th2 inflammation indicators (TNFAIP6, ALOX15), epithelial barrier genes (DSG1, CDH26, 
FLG), tissue fibrosis markers (e.g. KRT13), and IL-13/IL-4–induced genes (POSTN, MUC4) 
after PPI treatment, suggesting that PPI-REE and EoE share a common pathogenesis. The 
mastocytosis remission, at both protein and mRNA levels, supports the theory that PPI-REE 
is an allergic Th2-driven disorder. These findings align with previous data demonstrating the 
PPI-REE subjects have decreased mast cells and CD45RO-positive cells after PPI 
monotherapy17. Moreover, the similar signature of PPI-REE-pre vs. EoE also raises the 
questions of whether PPI-REE shares a comparable natural history to EoE and whether, if 
left unmanaged, PPI-REE can lead to adverse prognosis such as tissue fibrosis, as recently 
reported23–27.
Histological severity as measured by esophageal eosinophils/HPF correlated well with EoE 
score at an overall level (all cohorts); however, when EoE and PPI-REE-pre were analyzed 
individually, the correlation between histological severity (eosinophils/HPF) and EoE score 
was not significant in PPI-REE-pre yet was significant in EoE despite the gene 
dysregulation signature similarity between EoE and PPI-REE. These differences in 
correlation and the distribution of EoE scores in the PPI-REE-pre cohort suggest potential 
heterogeneity in the patient populations; Alternatively, PPI-REE may involve a 
combinatorial trigger of food and acid, which could potentially lead to differences in gene 
expression. Our current study is not powered to evaluate this potential heterogeneity. 
Interestingly, the EoE score was statistically different in EoE vs. PPI-REE-pre, with EoE 
showing a larger difference than PPI-REE-pre to controls. Thus, PPI-REE may be less 
severe, at least in terms of the molecular dysregulation as defined by the EDP. The finding 
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that PPI-REE may be potentially less severe is consistent with the modestly lower level of 
esophageal eosinophils and the lower incidence of endoscopic abnormalities in the PPI-REE 
group compared to the EoE group. This study is restricted by the EDP scope without 
genome-wide coverage; therefore we cannot rule out additional genome-wide mechanisms 
that may differentiate the two entities or explain the differential eosinophilia. Accordingly, 
using a genome-wide approach to query the ex vivo esophageal transcriptome in the 
presence and absence of PPI would be a promising approach as well.
Our results suggest that PPI-REE is allergic in nature and its clinical management may be 
more similar to EoE rather than GERD. Moreover, being able to differentiate EoE and PPI-
REE prior to PPI trial would be a meaningful advance for patients, possibly shortening time 
to diagnosis and effective treatment. Having predictor genes makes untreated PPI-REE and 
EoE potentially distinguishable before PPI treatment, leading to a new conceptual 
classification of esophageal eosinophilia. Moreover, being able to predict the PPI response 
may significantly enhance patient quality of life and will likely reduce medical costs due to 
the distinct therapies for PPI-REE and EoE. We initially identified a cluster of 10 genes 
capable of differentiating EoE and PPI-REE-pre. After a subsequent false-detection filter, 
differential KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2/Kir2.1) 
expression between EoE and PPI-REE-pre remained significant. Interestingly, Kir2.1 has a 
unique biological significance as this potassium channel was found to be coupled to the 
proton pump in the gastrointestinal epithelium14, 15. Moreover, Kir2.1 conductance property 
is subjected to pH change and is involved in acid secretion from parietal cells14. Kir2.1 
ensures that the potassium ion produced by the proton pump as a byproduct can be readily 
removed from the intracellular space. Therefore, a lower KCNJ2 expression level, as in the 
case of PPI-REE, could result in lower efficiency of the proton pump and help explain the 
efficacy of PPI.
In conclusion, in this multi-center study employing EDP signature analysis, we 
demonstrated that untreated PPI-REE shares a largely similar molecular transcriptome with 
EoE, suggesting that PPI-REE and EoE are highly related and have a common Th2/allergy 
pathogenesis. It is remarkable that the hallmark features of allergic inflammation are present 
in PPI-REE, showing that PPI therapy can reverse classic allergic inflammation at the 
molecular level. Clearly understanding the mechanism responsible for this is now a 
paramount question as this has implication for diseases associated with allergic 
inflammation. Based on our collective findings, we propose that many subjects with PPI-
REE represent a continuum of the same marked allergic inflammatory response that 
underlies EoE, and thus may constitute a sub-phenotype of EoE (Figure 5E). The EoE-like 
signature of untreated PPI-REE is reversible by PPI therapy, resulting in a remission 
signature close to that of normal controls. The molecular similarity of untreated PPI-REE 
and EoE mirrors the clinical, endoscopic, and histologic similarities between the two 
conditions. Interrogating the molecular signatures at an individual gene level may 
distinguish PPI-REE from EoE before PPI trial and reveal potentially different molecular 
pathways. As the debate regarding the nature of PPI-REE is ongoing, these findings are 
timely and clinically important, as understanding of the molecular etiology and pathogenesis 
of PPI-REE may help to better define the sub-form of esophageal eosinophilia, unveil the 
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pathogenesis of PPI-REE, and ultimately lead to improvement of diagnosis and therapeutic 
management of both PPI-REE and EoE.
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• PPI-REE shares a largely overlapping molecular signature with EoE
• PPI treatment alone is sufficient to reverse the allergic Th2 inflammatory 
signature of PPI-REE almost to baseline levels. This includes hallmark 
molecular features of allergic inflammation including eosinophilia, 
mastocytosis, tissue remodeling including periostin and impaired barrier 
function.
• A preliminary cluster of genes capable of differentiating PPI-REE and EoE 
before the PPI therapy has been identified.
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Figure 1. Comparison of esophageal transcriptomes of study cohorts
A total of 114 samples from five centers were analyzed by EoE diagnostic panel (EDP). 
Heat-maps were generated on the basis of the 59 EoE genes that passed a > 50% call rate of 
the EDP’s 77 significant genes (F59). Red color indicates higher expression (upregualtion) 
and blue represents lower expression (downregulation). EoE, EoE subjects; GERD, 
gastroesophageal reflux disease; NL, healthy controls; PPI-REE-pre, pre-therapy PPI-
responsive esophageal eosinophilia; PPI-REE-post, post-therapy PPI-responsive esophageal 
eosinophilia.
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Figure 2. Quantitative analysis of esophageal transcriptome and relationship to esophageal 
eosinophilia
A, the EoE scores (F59) were calculated for all five cohorts with the EDP algorithm reported 
previously 11. Circles represent individual subjects with an average line superimposed. One-
way ANOVA with Bonferroni’s multiple comparison post-test was employed with results 
summarized in the table on the lower panel (ns., not significant) B, The receiver operating 
characteristic (ROC) curve resulting from the comparison between mixed cohorts of NL and 
EoE from multiple centers. An optimal diagnostic cut-off of EoE score (F59) of 203 was 
derived herein. AUC, area under the curve. C, The eosinophil/high-power field (EOS/HPF) 
counts were demonstrated for all FFPE samples studied as peak esophageal biopsy count. D, 
Besides the significant differences found in EoE score (F59) and EOS/HPF for EoE vs. PPI-
REE-pre, a statistical difference was also identified when EoE score (F59) was normalized 
to peak EOS/HPF. E, A 3D-plot containing sample points from NL, EoE, PPI-REE-pre and 
PPI-REE-post cohorts was derived from principal component analysis (PCA) on the entities 
demonstrated in the heat-map to visualize the geometrical distance between any given 
cohort pair. F, Top panel, an overall correlation between EoE score and EOS/HPF for all 
FFPE samples included in this study. And in the two lower panels, breakdown graphs 
showing the correlation of EoE score (F59) of EoE samples and PPI-REE-pre samples with 
EOS/HPF separately.
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Figure 3. PPI-REE exhibits a continuum of EoE’s allergic inflammation signature
A and B, Within the scope of EDP F59, bioinformatic comparison (p < 0.05, Fold change > 
2.0, two-tailed unpaired t-test) yielded 50 and 47 significant genes, between EoE and NL; 
PPI-REE-pre and NL, respectively. A pair of volcano plots (Log2 fold change as x-axis; -
Log10 P value as y-axis) demonstrates the similarity of EoE’s and PPI-REE’s bi-directional 
dysregulation when compared to NL reference. C, A dysregulation (based on fold change 
over NL) linear correlation analysis between EoE (EoE/NL) and PPI-REE (PPI-REE/NL) 
was shown on the basis of the 46 overlapping EoE genes dysregulated in both EoE and PPI-
REE. D, On the basis of these 46 common genes, a gene ontology analysis focusing on 
biological function was performed with number of genes and corresponding p values shown, 
revealing a pathological basis for an adaptive Th2 allergic inflammation (p < 0.05 with 
Bonferroni correction).
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Figure 4. Effect of PPI therapy on the esophageal transcriptome of PPI-REE
A, The EoE scores before and after PPI-mono therapy for 13 paired samples (7 from UCSD 
and 6 from UNC). A diagnostic cut-off of EoE score = 203 was derived from ROC analysis 
between normal and EoE cohorts (dashed line). B, The EoE score amelioration is 
accompanied by mastocytosis remission shown by tryptase staining before and after PPI 
therapy (n =10, p < 0.01 by paired t-test). C, A representative pair of micropgraphs showing 
the tryptase staining before and after PPI in PPI-REE. D, The mRNA expression of mast cell 
gene CPA3 among all cohorts. E, The mRNA expression of mast cell gene TPSB2 (tryptase) 
among all cohorts. F, Although the overall signature normalizes in PPI-REE-post subjects 
(vs. NL), there are 8 genes that remain statistically dysregulated. The volcano plot depicts 
bidirectional fold-change (Log2) on x axis, and negative Log10 p value (NL vs. PPI-REE-
post) on y axis. Significance (red square genes) was defined by p < 0.05 and fold change > 
2.0.
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Figure 5. A gene cluster differentially expressed between EoE and PPI-REE-pre
A, A list of 10 EoE genes (within the EDP) whose expression is significantly different 
between EoE and PPI-REE-pre (two-tailed student t-test, p < 0.05, fold change > 2.0, n = 33 
for EoE and 28 for PPI-REE-pre). Arrowhead: KCNJ2. B, A predicative protein-protein 
interaction derived from the pathway analysis of the 10 significant genes, EoE vs. PPI-REE-
pre (http://toppgenes.cchmc.org). C, With false-discovery correction filter (Westfall-Young 
Permutative), KCNJ2 (Kir2.1) is the only significant gene within the scope of the EDP (EoE 
vs. PPI-REE-pre, corrected p = 0.04; * p < 0.05, ** p < 0.01, *** p < 0.001, mean±SEM). 
D, A hypothetical illustration suggesting the interaction of the proton pump (H+-K+-
ATPase) and Kir2.1 in gastrointestinal mucosa. E, A proposed schematic illustration of the 
classification and treatment of esophageal eosinophilia.
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